# Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

> **NCT00195676** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 1469 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** adalimumab

## Key facts

- **NCT ID:** NCT00195676
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 1469 (ACTUAL)
- **Last updated:** 2011-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195676, "Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00195676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*